The Manufacturers Life Insurance Company Has $16.64 Million Stock Holdings in Zoetis Inc. $ZTS

The Manufacturers Life Insurance Company decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 231,501 shares of the company’s stock after selling 14,462 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Zoetis were worth $16,636,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis in the 2nd quarter worth approximately $25,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the period. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis in the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the first quarter worth $28,000. Finally, Root Financial Partners LLC increased its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ZTS. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Piper Sandler decreased their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday, August 25th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Finally, BNP Paribas Exane reduced their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $101.08.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $73.05 on Friday. The business has a fifty day simple moving average of $75.56 and a 200 day simple moving average of $91.97. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market capitalization of $30.19 billion, a price-to-earnings ratio of 12.03, a PEG ratio of 1.70 and a beta of 0.73. Zoetis Inc. has a one year low of $71.00 and a one year high of $150.05.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.